Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5-ALA-Phosphate + SFC Immune Enhancement in COVID-19 Vaccination
NCT05234346Completed
- Sponsor
- Vedic Lifesciences
- Start
- Mar 2022
- Primary completion
- Jun 2022
- Modality
- Orthosteric Ligands, Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Randomised, open-label trial of aminolevulinic acid and sodium ferrous citrate in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Vedic Lifesciences. Primary endpoint: Adverse product reaction at Day 21. Started Mar 2022; status: completed.
02
Drugs
aminolevulinic acidsodium ferrous citrate
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05234346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05234346.